查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949456

診斷酵素市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、產品、最終用途、地區和競爭格局分類），2021-2031年

Diagnostic Enzymes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By Product, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球診斷酵素市場預計將從 2025 年的 57.1 億美元成長到 2031 年的 87.2 億美元，複合年成長率為 7.31%。

診斷酵素作為專門設計的生物催化劑，用於檢測和定量生物樣本中的特定分析物，是分子診斷和臨床化學中不可或缺的試劑。該市場的主要成長要素是全球慢性文明病發生率的上升，而這些疾病需要頻繁且精準的酵素檢測才能有效管理。根據國際糖尿病聯盟（IDF）預測，到2024年，糖尿病將影響全球約11.1%的成年人口（5.89億人）。這種廣泛的流行顯著推動了對葡萄糖氧化酵素監測酶的需求，凸顯了這些生物工具在現代醫療保健系統中的關鍵作用。

市場概覽
預測期 2027-2031
市場規模：2025年 57.1億美元
市場規模：2031年 87.2億美元
複合年成長率：2026-2031年 7.31%
成長最快的細分市場 Taq聚合酵素
最大的市場 北美洲

然而，由於這些蛋白質在環境條件波動時固有的不穩定性，市場面臨許多重大障礙。診斷酵素易受溫度和pH值變化的影響而變性，因此需要嚴格的低溫運輸物流進行儲存和運輸。這些特殊的處理要求增加了製造商的營運成本，並限制了基礎設施不足的發展中地區的產品供應。因此，如何在整個供應鏈中維持酵素的活性，是相關人員為維持全球市場成長而必須克服的重大技術和經濟挑戰。

市場促進因素

製藥和生技領域研發投入的大幅成長，正成為推動診斷酵素發展的重要催化劑。製造商正投入大量研發分子診斷技術，以提高基因測序中使用的逆轉錄酶和聚合酵素的穩定性和特異性。這些資金支持使得重組酶的設計成為可能，這些酶能夠在各種檢測條件下有效發揮作用，從而最大限度地降低關鍵臨床應用中的錯誤率。根據羅氏公司於2024年2月發布的2023年度報告，該公司已投入132億瑞士法郎用於研發，以推動其製藥和診斷產品組合的創新。這筆大規模資源投入直接支援液態生物檢體和次世代定序平台所需的專用生物催化劑的開發，確保診斷工具能夠滿足現代醫學的複雜需求。

同時，全球感染疾病和慢性病疫情日益嚴峻，亟需增加此類檢測試劑的供應和生產。隨著複雜疾病發生率的上升，臨床檢查室需要可靠的酵素製劑工具進行病毒篩檢和病理診斷，以確保早期療育。根據美國癌症協會2024年1月發布的《2024年癌症事實與數據》，預計美國新增癌症病例數將首次超過200萬例。此外，傳染病持續帶來的負擔也對檢測基礎設施提出了更高的要求。世界衛生組織（世衛組織）2024年4月發布的《2024年全球肝炎報告》估計，到2022年，全球慢性B型肝炎病例將達到2.54億例。這些流行病學趨勢與診斷酶消耗量的增加直接相關，而診斷酶對於及時診斷和治療監測至關重要。

市場挑戰

診斷酵素固有的不穩定性是限制全球診斷酵素市場擴張的主要挑戰。這些基於蛋白質的生物催化劑極易在pH值變化和溫度波動時發生變性，導致觸媒活性不可逆喪失。因此，製造商不得不實施嚴格的低溫運輸物流，以確保產品在運輸和儲存過程中的品質。這種對專業處理基礎設施的依賴必然會增加營運成本，並使供應鏈管理更加複雜。

此外，這項要求對發展中地區構成重大准入壁壘，因為這些地區往往缺乏可靠的物流網路和電力供應。維持受控環境的高成本和技術複雜性限制了這些關鍵試劑的獲取，從而抑制了新興市場的潛在成長。這一瓶頸對相關產業造成的經濟影響巨大。根據歐洲醫療技術協會（MedTech Europe）預測，到2024年，歐洲醫療技術市場規模預計將達到約1,700億歐元，使體外診斷成為全球最大的產業。因此，維持酵素穩定性的財務和物流負擔持續阻礙市場充分利用全球需求的能力。

市場趨勢

CRISPR-Cas系統在診斷領域的應用正透過引入可程式設計酶工具，克服傳統PCR的局限性，從而改變市場模式。與需要複雜熱感循環的標準聚合酵素不同，CRISPR相關酵素（例如Cas12和Cas13）能夠以單核苷酸靈敏度進行快速、等溫核酸檢測，使其成為分散式檢查的理想選擇。這項技術變革正在加速開發無需儀器的診斷解決方案，將實驗室層級的精準度直接帶入消費者生活環境。在2024年5月題為「一次性分子性行為感染疾病檢測套組臨床試驗啟動：與中心檢查室檢測的比較」的新聞稿中，Sherlock Biosciences宣布啟動一項針對市售CRISPR性行為感染疾病診斷試劑盒的臨床試驗。這標誌著這項創新酶技術在家庭使用商業化過程中邁出了重要一步。

同時，人工智慧和機器學習在酶發現領域的應用正在從根本上改變製造商設計生物催化劑以提高性能的方式。生成式人工智慧模型現在可以「從頭」設計具有精確穩定性和動力學特徵的酶，從而有效地繞過了傳統定向進化緩慢高成本的迭代過程。這項技術飛躍使企業能夠快速創建針對嚴苛診斷環境以及難以識別和檢測的分析物進行最佳化的新型蛋白質。例如，BioMatter公司於2024年8月宣布已獲得650萬歐元的融資，用於擴展其「智慧架構」平台。該平台利用生成式人工智慧建構世界上首批不受自然蛋白質進化限制的酵素。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球診斷酵素市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（Taq聚合酵素、MMLV 逆轉錄酶、HIV 逆轉錄酶、熱啟動 Taq聚合酵素、UNG、RNase 抑制劑、Bst聚合酵素、PCR 預混液、冷凍乾燥聚合酵素、T7 RNA聚合酵素、Cas9酵素、酸性磷酸酶、丙胺基轉移酶、澱粉酶、血管收縮素轉化酵素、胺基轉移酶轉移酶、膽鹼酯酶、肌酸激酶、γ-谷氨醯轉移酶、乳酸脫氫酵素、腎素、葡萄糖氧化酵素/葡萄糖去氫酵素、尿素酶、乳酸氧化酶、辣根過氧化物酶、麩胺酸氧化酶、其他）
    • 依應用領域（糖尿病、腫瘤、心臟病、感染疾病、自體免疫疾病等）
    • 依產品（分子酵素、臨床酵素）
    • 依最終用途（醫院、臨床檢查室、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美診斷酵素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲診斷酶市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區診斷酵素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲診斷酵素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲診斷酶市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球診斷酵素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Takara Bio Inc.
  • Promega Corporation
  • Enzo Biochem Inc.
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Amano Enzyme Inc.
  • F. Hoffmann-La Roche Ltd.
  • Solis BioDyne OU
  • Ampliqon A/S
  • Yashraj Biotechnology Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 16273

The Global Diagnostic Enzymes Market is projected to expand from USD 5.71 Billion in 2025 to USD 8.72 Billion by 2031, reflecting a compound annual growth rate (CAGR) of 7.31%. Diagnostic enzymes function as specialized biocatalysts designed to detect and quantify specific analytes within biological samples, acting as essential reagents in molecular diagnostics and clinical chemistry. The market is primarily driven by the rising global incidence of chronic lifestyle diseases, which demands frequent and precise enzymatic testing for effective disease management. According to the International Diabetes Federation, diabetes impacted roughly 11.1% of the global adult population in 2024, amounting to 589 million individuals. This widespread prevalence significantly boosts the demand for monitoring enzymes such as glucose oxidase, underscoring the vital role these biological tools play in modern healthcare infrastructure.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 5.71 Billion
Market Size 2031USD 8.72 Billion
CAGR 2026-20317.31%
Fastest Growing SegmentTaq Polymerase
Largest MarketNorth America

However, the market faces a substantial obstacle due to the inherent instability of these proteins when subjected to fluctuating environmental conditions. Diagnostic enzymes are prone to denaturation caused by changes in temperature and pH, necessitating strict cold-chain logistics for storage and transport. This requirement for specialized handling increases operational costs for manufacturers and limits product accessibility in developing regions that lack adequate infrastructure. Consequently, maintaining enzymatic activity across the supply chain presents a significant technical and economic challenge that stakeholders must overcome to sustain global market growth.

Market Driver

Significant growth in pharmaceutical and biotechnology R&D investments acts as a major catalyst for the advancement of diagnostic enzymes. Manufacturers are allocating substantial capital to molecular diagnostics to improve the stability and specificity of reverse transcriptases and polymerases used in genomic sequencing. This financial support enables the engineering of recombinant enzymes capable of functioning efficiently across various assay conditions, thereby minimizing error rates in crucial clinical applications. According to Roche's 'Annual Report 2023' released in February 2024, the company invested CHF 13.2 billion in research and development to foster innovation across its pharmaceutical and diagnostic portfolios. Such significant resource allocation directly supports the development of specialized biocatalysts needed for liquid biopsy and next-generation sequencing platforms, ensuring diagnostic tools meet complex modern medical requirements.

Simultaneously, the escalating global prevalence of infectious and chronic diseases demands an increased supply and production of these detection reagents. As the incidence of complex conditions rises, clinical laboratories require reliable enzymatic tools for viral screening and pathology to ensure early intervention. According to the American Cancer Society's 'Cancer Facts & Figures 2024' published in January 2024, projections indicate that new cancer cases in the United States will exceed 2 million for the first time. Furthermore, the persistent burden of communicable diseases maintains the demand for testing infrastructure; the World Health Organization's 'Global Hepatitis Report 2024' from April 2024 estimated that 254 million people worldwide were living with chronic hepatitis B in 2022. These epidemiological trends directly correlate with increased consumption of diagnostic enzymes essential for timely diagnosis and treatment monitoring.

Market Challenge

The inherent instability of diagnostic enzymes represents a major challenge restricting the broader expansion of the Global Diagnostic Enzymes Market. These protein-based biocatalysts are highly susceptible to denaturation when exposed to pH changes or temperature fluctuations, resulting in an irreversible loss of catalytic activity. Consequently, manufacturers are forced to implement rigorous cold-chain logistics to ensure product integrity during transport and storage. This dependence on specialized handling infrastructure inevitably raises operational costs and complicates supply chain management.

Moreover, this requirement creates a formidable barrier to entry in developing regions where reliable logistics networks and electricity are often lacking. The high cost and technical complexity of maintaining a controlled environment limit the accessibility of these critical reagents, thereby stifling potential growth in emerging markets. The economic impact on the sector facing this bottleneck is substantial. According to MedTech Europe, the European medical technology market was estimated to be roughly €170 billion in 2024, with in vitro diagnostics identified as the largest sector worldwide. Thus, the financial and logistical burden of preserving enzyme stability continues to impede the market's ability to fully capitalize on global demand.

Market Trends

The emergence of CRISPR-Cas systems for diagnostic applications is transforming the market by introducing programmable enzymatic tools that surpass the limitations of traditional PCR methods. Unlike standard polymerases that require complex thermal cycling, CRISPR-associated enzymes such as Cas12 and Cas13 enable rapid, isothermal nucleic acid detection with single-nucleotide sensitivity, making them ideal for decentralized testing. This technical shift is accelerating the development of instrument-free diagnostic solutions that bring laboratory-grade accuracy directly to consumer settings. According to Sherlock Biosciences, in a May 2024 press release titled 'Sherlock Biosciences Starts Clinical Trial of Disposable Molecular STI Test vs. Central Lab Tests', the company initiated a clinical trial for its over-the-counter CRISPR-based diagnostic test for sexually transmitted infections, marking a significant step toward commercializing this novel enzymatic technology for home use.

Concurrently, the application of AI and Machine Learning in enzyme discovery is fundamentally reshaping how manufacturers engineer biocatalysts for enhanced performance. Generative AI models are now capable of designing enzymes with precise stability and kinetic profiles "de novo," effectively bypassing the slow and costly iterations of traditional directed evolution. This technological leap allows companies to rapidly generate novel proteins tailored for harsh diagnostic environments or specific, hard-to-detect analytes. Demonstrating this momentum, according to Biomatter's August 2024 announcement 'Biomatter raises a €6.5 million seed round to unlock the power of generative AI for enzyme design', the company secured €6.5 million to expand its Intelligent Architecture platform, which leverages generative AI to construct new-to-the-world enzymes without the constraints of natural protein evolution.

Key Market Players

  • Takara Bio Inc.
  • Promega Corporation
  • Enzo Biochem Inc.
  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Amano Enzyme Inc.
  • F. Hoffmann-La Roche Ltd.
  • Solis BioDyne OU
  • Ampliqon A/S
  • Yashraj Biotechnology Ltd

Report Scope

In this report, the Global Diagnostic Enzymes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diagnostic Enzymes Market, By Type

  • Taq Polymerase
  • MMLV RT
  • HIV RT
  • Hot start Taq Polymerase
  • UNG
  • RNase Inhibitors
  • Bst Polymerase
  • PCR Master Mix
  • Lyophilized Polymerase
  • T7 RNA Polymerase
  • Cas9 Enzyme
  • Acid Phosphatase
  • Alanine Aminotransferase
  • Amylase
  • Angiotensin Converting Enzyme
  • Aspartate Aminotransferase
  • Cholinesterase
  • Creatinine Kinase
  • Gamma Glutamyl Transferase
  • Lactate Dehydrogenase
  • Renin
  • Glucose Oxidase/Glucose Dehydrogenase
  • Urease
  • Lactate Oxidase
  • Horseradish Peroxide
  • Glutamate Oxidase
  • Others

Diagnostic Enzymes Market, By Application

  • Diabetes
  • Oncology
  • Cardiology
  • Infectious Diseases
  • Autoimmune Diseases
  • Others

Diagnostic Enzymes Market, By Product

  • Molecular Enzymes
  • Clinical Enzymes

Diagnostic Enzymes Market, By End Use

  • Hospitals
  • Clinical Laboratories
  • Others

Diagnostic Enzymes Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diagnostic Enzymes Market.

Available Customizations:

Global Diagnostic Enzymes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diagnostic Enzymes Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Taq Polymerase, MMLV RT, HIV RT, Hot start Taq Polymerase, UNG, RNase Inhibitors, Bst Polymerase, PCR Master Mix, Lyophilized Polymerase, T7 RNA Polymerase, Cas9 Enzyme, Acid Phosphatase, Alanine Aminotransferase, Amylase, Angiotensin Converting Enzyme, Aspartate Aminotransferase, Cholinesterase, Creatinine Kinase, Gamma Glutamyl Transferase, Lactate Dehydrogenase, Renin, Glucose Oxidase/Glucose Dehydrogenase, Urease, Lactate Oxidase, Horseradish Peroxide, Glutamate Oxidase, Others)
    • 5.2.2. By Application (Diabetes, Oncology, Cardiology, Infectious Diseases, Autoimmune Diseases, Others)
    • 5.2.3. By Product (Molecular Enzymes, Clinical Enzymes)
    • 5.2.4. By End Use (Hospitals, Clinical Laboratories, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Diagnostic Enzymes Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By Product
    • 6.2.4. By End Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Diagnostic Enzymes Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Product
        • 6.3.1.2.4. By End Use
    • 6.3.2. Canada Diagnostic Enzymes Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Product
        • 6.3.2.2.4. By End Use
    • 6.3.3. Mexico Diagnostic Enzymes Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Product
        • 6.3.3.2.4. By End Use

7. Europe Diagnostic Enzymes Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By Product
    • 7.2.4. By End Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Diagnostic Enzymes Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Product
        • 7.3.1.2.4. By End Use
    • 7.3.2. France Diagnostic Enzymes Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Product
        • 7.3.2.2.4. By End Use
    • 7.3.3. United Kingdom Diagnostic Enzymes Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Product
        • 7.3.3.2.4. By End Use
    • 7.3.4. Italy Diagnostic Enzymes Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Product
        • 7.3.4.2.4. By End Use
    • 7.3.5. Spain Diagnostic Enzymes Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Product
        • 7.3.5.2.4. By End Use

8. Asia Pacific Diagnostic Enzymes Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By Product
    • 8.2.4. By End Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Diagnostic Enzymes Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Product
        • 8.3.1.2.4. By End Use
    • 8.3.2. India Diagnostic Enzymes Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Product
        • 8.3.2.2.4. By End Use
    • 8.3.3. Japan Diagnostic Enzymes Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Product
        • 8.3.3.2.4. By End Use
    • 8.3.4. South Korea Diagnostic Enzymes Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Product
        • 8.3.4.2.4. By End Use
    • 8.3.5. Australia Diagnostic Enzymes Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Product
        • 8.3.5.2.4. By End Use

9. Middle East & Africa Diagnostic Enzymes Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By Product
    • 9.2.4. By End Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Diagnostic Enzymes Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Product
        • 9.3.1.2.4. By End Use
    • 9.3.2. UAE Diagnostic Enzymes Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Product
        • 9.3.2.2.4. By End Use
    • 9.3.3. South Africa Diagnostic Enzymes Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Product
        • 9.3.3.2.4. By End Use

10. South America Diagnostic Enzymes Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By Product
    • 10.2.4. By End Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Diagnostic Enzymes Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Product
        • 10.3.1.2.4. By End Use
    • 10.3.2. Colombia Diagnostic Enzymes Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Product
        • 10.3.2.2.4. By End Use
    • 10.3.3. Argentina Diagnostic Enzymes Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Product
        • 10.3.3.2.4. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Diagnostic Enzymes Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Takara Bio Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Promega Corporation
  • 15.3. Enzo Biochem Inc.
  • 15.4. Merck KGaA
  • 15.5. Thermo Fisher Scientific, Inc.
  • 15.6. Amano Enzyme Inc.
  • 15.7. F. Hoffmann-La Roche Ltd.
  • 15.8. Solis BioDyne OU
  • 15.9. Ampliqon A/S
  • 15.10. Yashraj Biotechnology Ltd

16. Strategic Recommendations

17. About Us & Disclaimer